The estimated Net Worth of Robert N Neville is at least 2.47 百万$ dollars as of 21 December 2018. Robert Neville owns over 23,517 units of Savara Inc stock worth over 2,151,481$ and over the last 7 years Robert sold SVRA stock worth over 323,250$.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Robert Neville SVRA stock SEC Form 4 insiders trading
Robert has made over 4 trades of the Savara Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently Robert bought 23,517 units of SVRA stock worth 150,038$ on 21 December 2018.
The largest trade Robert's ever made was exercising 92,351 units of Savara Inc stock on 8 June 2018 worth over 60,028$. On average, Robert trades about 32,186 units every 94 days since 2017. As of 21 December 2018 Robert still owns at least 498,028 units of Savara Inc stock.
You can see the complete history of Robert Neville stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Robert Neville's mailing address?
Robert's mailing address filed with the SEC is 6836 BEE CAVE ROAD, BUILDING III, SUITE 200, AUSTIN, TX, 78746.
Insiders trading at Savara Inc
Over the last 8 years, insiders at Savara Inc have traded over 2,203,958$ worth of Savara Inc stock and bought 6,103,761 units worth 15,290,245$ . The most active insiders traders include Forest Baskett、Scott D Sandell、Anthony A. Jr. Florence. On average, Savara Inc executives and independent directors trade stock every 29 days with the average trade being worth of 348,922$. The most recent stock trade was executed by Matthew Pauls on 28 December 2023, trading 84,000 units of SVRA stock currently worth 395,640$.
What does Savara Inc do?
savara pharmaceuticals is an emerging specialty pharmaceutical company developing innovative pulmonary drugs for the treatment of serious and life-threatening conditions. the company’s lead product, aerovanc is the first dry powder inhaled antibiotic for the treatment of methicillin-resistant staphylococcus aureus (mrsa) infection in patients with cystic fibrosis (cf). for more information, please see savara’s website at www.savarapharma.com or www.aerovanc.com
What does Savara Inc's logo look like?
Complete history of Robert Neville stock trades at Savara Inc
Savara Inc executives and stock owners
Savara Inc executives and other stock owners filed with the SEC include:
-
Dr. Badrul A. Chowdhury M.D., Ph.D.,
Chief Medical Officer -
David Lowrance,
Chief Financial Officer, Secretary -
David L. Lowrance,
CFO & Sec. -
Ricky Sun,
Independent Director -
Annigje van Es-Johansson,
Independent Director -
Badrul Chowdhury,
Chief Medical Officer -
Anne Erickson,
IR Contact Officer -
David Ramsay,
Independent Director -
Matthew Pauls,
Chairman of the Board, Interim Chief Executive Officer -
Joseph McCracken,
Independent Director -
Richard Hawkins,
Independent Director -
Nevan Elam,
Independent Director -
Dr. Peter Clarke Ph.D.,
Exec. VP of Global Technical Operations -
Charles LaPree,
Sr. VP of Global Regulatory Affairs & Quality Assurance -
Brian Maurer,
Head of Clinical Operations -
Dr. Dhaval Desai M.D.,
Head of Clinical Devel. -
Kate McCabe,
Sr. VP of Legal Affairs -
Robert N Neville,
Chief Executive Officer -
Yuri Pikover,
Director -
Jaakko Taneli Jouhikainen,
See Remarks -
Es Johansson An Van,
Director -
Forest Baskett,
10% owner -
Equity Opportunities 17, Ll...,
-
Rick Yang,
10% owner -
Paul Edward Walker,
10% owner -
Scott D Sandell,
10% owner -
Edward T Mathers,
10% owner -
Mohamad Makhzoumi,
10% owner -
Carmen Chang,
10% owner -
Anthony A. Jr. Florence,
10% owner -
Ali Behbahani,
10% owner -
Raymond Dennis Pratt,
Chief Medical Officer -
Robert Matthew Lutz,
Chief Operating Officer